// App-Quantinova.ai

1040 : Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis

Researchers

Presenter

  • Uta Kiltz

Principal Investigators

  • Petros P. Sfikakis

  • Nicola Gullick

  • ATHINA THEODORIDOU

  • Anna Kandyli

  • Jan Brandt-Juergens

  • Philippe Goupille

  • Nicola Maiden

  • Karl Gaffney

  • Daniel Peterlik

  • Barbara Schulz

  • Effie Pournara

  • Piotr Jagiello

Medical Centers

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • Joint Academic Rheumatology Program, National and Kapodestrian University of Athens, Athens, Greece

  • University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom

  • Euromedica Geniki Kliniki, General Hospital, Thessaloniki, Greece

  • Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece

  • Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany

  • Rheumatology department, University Hospital of Tours, Tours, France

  • Craigavon Area Hospital, Southern Health & Social Care Trust, Craigavon, United Kingdom

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • Novartis Pharma GmbH, Nuernberg, Germany

  • Novartis AG, Basel, Switzerland

Locations

  • Germany

  • Greece

  • United Kingdom

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved